Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.

@article{Lundin2010EfficacyAS,
  title={Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.},
  author={Anders Lundin and E Dietrichs and Sara Motevali Haghighi and Marie-Louise G{\"o}ller and Arvid Heiberg and Ghada Loutfi and H{\aa}kan Widner and Klas Wiktorin and Leif Wiklund and Anders Svenningsson and Clas Sonesson and Nicholas Waters and Susanna Holm Waters and Joakim Tedroff},
  journal={Clinical neuropharmacology},
  year={2010},
  volume={33 5},
  pages={260-4}
}
OBJECTIVES To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease (HD). METHODS In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in… CONTINUE READING